ASH 2022 | Evaluating the safety of maintenance therapy cessation in MRD negative myeloma patients
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of a study that investigated whether discontinuing lenalidomide maintenance therapy post-transplant is safe in multiple myeloma (MM) patients with sustained measurable residual disease (MRD) negativity. The majority of the first 25 patients did not have MRD recurrence at 12 months, which was the study’s primary endpoint. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Memorial Sloan Kettering Cancer Center: Current Employment; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria; Serametrix, inc: Patents & Royalties; Trillium Therapeutics: Consultancy, Research Funding; Sanofi: Research Funding; BMS: Honoraria; Amgen: Honoraria.
